Clinical Trial

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04-30 -> 2027-07-30 2026-05-16
minor Completion pushed: 2026-10-31 -> 2027-12-31 2026-05-16
Trial Details
NCT Number NCT06918808
Lead Sponsor Direct Biologics, LLC
Conditions Perianal Fistula Due to Crohn's Disease
Enrollment 36 participants
Start Date 2025-05-19
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-15